Anton Bespalov

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8966830/publications.pdf

Version: 2024-02-01

106 papers	3,322 citations	147726 31 h-index	175177 52 g-index
112 all docs	112 docs citations	112 times ranked	3865 citing authors

#	Article	IF	Citations
1	Improving target assessment in biomedical research: the GOT-IT recommendations. Nature Reviews Drug Discovery, 2021, 20, 64-81.	21.5	86
2	Introduction to the EQIPD quality system. ELife, 2021, 10, .	2.8	42
3	Pharmacology of Anxiety or Pharmacology of Elevated Plus Maze?. Biological Psychiatry, 2021, 89, e73.	0.7	8
4	PEERS â€" An Open Science â€œPlatform for the Exchange of Experimental Research Standardsâ€•in Biomedicine. Frontiers in Behavioral Neuroscience, 2021, 15, 755812.	1.0	7
5	Towards best practices in research. EMBO Reports, 2021, 22, e53824.	2.0	3
6	A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinsonâ€™s disease: translational gaps or a failing industry innovation model?. Expert Opinion on Investigational Drugs, 2020, 29, 1323-1338.	1.9	12
7	Enhancing quality in preclinical data: Of hot science and cool quality. Temperature, 2020, 7, 301-303.	1.6	0
8	Systematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animalsSystematic review of guidelines for internal validity in the design, conduct and analysis of preclinical biomedical experiments involving laboratory animals. BMJ Open Science, 2020, 44, e100046.	0.8	40
9	Blinding and Randomization. Handbook of Experimental Pharmacology, 2019, 257, 81-100.	0.9	24
10	Improving transparency and scientific rigor in academic publishing. Brain and Behavior, 2019, 9, e01141.	1.0	23
11	Improving transparency and scientific rigor in academic publishing. Journal of Neuroscience Research, 2019, 97, 377-390.	1.3	39
12	Improving transparency and scientific rigor in academic publishing. Cancer Reports, 2019, 2, e1150.	0.6	5
13	Be positive about negativesâ€“recommendations for the publication of negative (or null) results. European Neuropsychopharmacology, 2019, 29, 1312-1320.	0.3	28
14	Activation of trace amine-associated receptor 1 attenuates schedule-induced polydipsia in rats. Neuropharmacology, 2019, 144, 184-192.	2.0	12
15	Targeting Glycine Reuptake in Alcohol Seeking and Relapse. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 202-211.	1.3	13
16	Efficacy and side effects of baclofen and the novel GABAB receptor positive allosteric modulator CMPPE in animal models for alcohol and cocaine addiction. Psychopharmacology, 2018, 235, 1955-1965.	1.5	23
17	Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy. Biological Psychiatry, 2018, 83, 955-962.	0.7	25
18	Lacking quality in research: Is behavioral neuroscience affected more than other areas of biomedical science?. Journal of Neuroscience Methods, 2018, 300, 4-9.	1.3	20

#	Article	IF	Citations
19	Industry is more alarmed about reproducibility than academia. Nature, 2018, 563, 626-626.	13.7	9
20	Towards trans-diagnostic mechanisms in psychiatry: Neurobehavioral profile of rats with a loss of function point mutation in the dopamine transporter gene. DMM Disease Models and Mechanisms, 2017, 10, 451-461.	1.2	27
21	Novel reinforcement learning paradigm based on response patterning under interval schedules of reinforcement. Behavioural Brain Research, 2017, 331, 276-281.	1.2	6
22	mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?. Psychopharmacology, 2017, 234, 1333-1345.	1.5	5
23	Potential role of tyrosine hydroxylase in the loss of psychostimulant effect of amphetamine under conditions of impaired dopamine transporter activity. Behavioural Brain Research, 2017, 334, 105-108.	1.2	1
24	The effects of PDE10 inhibition on attentional set-shifting do not depend on the activation of dopamine D1 receptors. Behavioural Pharmacology, 2016, 27, 331-338.	0.8	11
25	Enhanced brain penetration of hexamethonium in complexes with derivatives of fullerene C60. Doklady Biochemistry and Biophysics, 2016, 468, 173-175.	0.3	12
26	Morphine-induced Straub tail reaction in mice treated with serotonergic compounds. European Journal of Pharmacology, 2016, 791, 1-7.	1.7	14
27	Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets. Nature Reviews Drug Discovery, 2016, 15, 516-516.	21.5	58
28	Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditions. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 457-466.	1.4	1
29	Drug Tolerance: A Known Unknown in Translational Neuroscience. Trends in Pharmacological Sciences, 2016, 37, 364-378.	4.0	38
30	The Calpain Inhibitor A-705253 Attenuates Alcohol-Seeking and Relapse with Low Side-Effect Profile. Neuropsychopharmacology, 2016, 41, 979-988.	2.8	10
31	Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2015, 24, 1515-1528.	1.9	39
32	The preclinical data forum network: A new ECNP initiative to improve data quality and robustness for (preclinical) neuroscience. European Neuropsychopharmacology, 2015, 25, 1803-1807.	0.3	18
33	Agonist and antagonist effects of cytisine inÂvivo. Neuropharmacology, 2015, 95, 206-214.	2.0	13
34	Impaired Cognition after Stimulation of P2Y1 Receptors in the Rat Medial Prefrontal Cortex. Neuropsychopharmacology, 2015, 40, 305-314.	2.8	28
35	Mechanistic Insights Into the Analgesic Efficacy of A-1264087, a Novel Neuronal Ca2+ Channel Blocker That Reduces Nociception in Rat Preclinical Pain Models. Journal of Pain, 2014, 15, 387.e1-387.e14.	0.7	10
36	Development of novel therapy of schizophrenia in children and adolescents. Expert Opinion on Investigational Drugs, 2014, 23, 1531-1540.	1.9	1

#	Article	IF	Citations
37	Effects of Catechol-O-Methyltransferase Deficiency on the Reinforcing Effects of Cocaine (an) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.2	0
38	Development of Disease-Modifying Treatment of Schizophrenia. Handbook of Experimental Pharmacology, 2012, , 419-442.	0.9	8
39	Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner. Neuropharmacology, 2011, 61, 262-267.	2.0	23
40	Interaction of Blockers of Ionotropic NMDA Receptors and Metabotropic Glutamate Receptors in a Working Memory Test in Rats. Neuroscience and Behavioral Physiology, 2010, 40, 807-811.	0.2	5
41	Editorial for Special Issue on mGluRs and cognition. European Journal of Pharmacology, 2010, 639, 1.	1.7	1
42	Effects of a Positive Allosteric Modulator of Group II Metabotropic Glutamate Receptors, LY487379, on Cognitive Flexibility and Impulsive-Like Responding in Rats. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 665-673.	1.3	71
43	Generation and Therapeutic Efficacy of Highly Oligomer-Specific Î²-Amyloid Antibodies. Journal of Neuroscience, 2010, 30, 10369-10379.	1.7	97
44	Double Dissociation of the Effects of Haloperidol and the Dopamine D3 Receptor Antagonist ABT-127 on Acquisition vs. Expression of Cocaine-Conditioned Activity in Rats. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 506-515.	1.3	18
45	Glutamatergic (N-Methyl-d-aspartate Receptor) Hypofrontality in Schizophrenia: Too Little Juice or a Miswired Brain?. Molecular Pharmacology, 2010, 77, 317-326.	1.0	145
46	Antidepressant Treatment in Anxiety Disorders. Current Topics in Behavioral Neurosciences, 2009, 2, 361-390.	0.8	24
47	Effects of mGlu1 receptor blockade on working memory, time estimation, and impulsivity in rats. Psychopharmacology, 2008, 196, 211-220.	1.5	42
48	Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. European Journal of Pharmacology, 2008, 592, 96-102.	1.7	62
49	Habituation Deficits Induced by Metabotropic Glutamate Receptors 2/3 Receptor Blockade in Mice: Reversal by Antipsychotic Drugs. Journal of Pharmacology and Experimental Therapeutics, 2007, 320, 944-950.	1.3	48
50	Effect of Memantine on Cue-Induced Alcohol Craving in Recovering Alcohol-Dependent Patients. American Journal of Psychiatry, 2007, 164, 519-523.	4.0	106
51	mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology, 2007, 52, 263-269.	2.0	91
52	Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. European Neuropsychopharmacology, 2007, 17, 172-179.	0.3	173
53	Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology, 2007, 192, 511-519.	1.5	93
54	AMPA receptor antagonists reverse effects of extended habit training on signaled food approach responding in rats. Psychopharmacology, 2007, 195, 11-18.	1.5	8

#	Article	IF	Citations
55	Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice. European Neuropsychopharmacology, 2006, 16, 297-310.	0.3	77
56	Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 2006, 31, 319-328.	1.5	95
57	Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain â€“ relation to brain concentration. Neuropharmacology, 2006, 51, 1163-1171.	2.0	47
58	Lowered brain stimulation reward thresholds in rats treated with a combination of caffeine and N-methyl-D-aspartate but not alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate or metabotropic glutamate receptor-5 receptor antagonists. Behavioural Pharmacology, 2006, 17, 295-302.	0.8	12
59	Effects of group I metabotropic glutamate receptor antagonists on the behavioral sensitization to motor effects of cocaine in rats. Psychopharmacology, 2006, 187, 397-404.	1.5	46
60	Effects of memantine on estrogen-dependent acute tolerance to the morphine analgesia in female rats. European Journal of Pharmacology, 2006, 535, 78-85.	1.7	13
61	Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. European Journal of Pharmacology, 2005, 514, 25-34.	1.7	103
62	Anti-allodynic interactions between NMDA receptor channel blockers and morphine or clonidine in neuropathic rats. European Journal of Pharmacology, 2005, 519, 80-85.	1.7	12
63	Analgesic effects of morphine and loperamide in the rat formalin test: Interactions with NMDA receptor antagonists. European Journal of Pharmacology, 2005, 525, 83-90.	1.7	36
64	Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats. Psychopharmacology, 2005, 179, 128-135.	1.5	35
65	Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. European Neuropsychopharmacology, 2005, 15, 219-225.	0.3	75
66	Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology, 2005, 49, 167-178.	2.0	126
67	Intravenous self-administration of abused solvents and anesthetics in mice. European Journal of Pharmacology, 2004, 485, 211-218.	1.7	57
68	Estrous cycle stage-dependent expression of acute tolerance to morphine analgesia in rats. European Journal of Pharmacology, 2004, 486, 259-264.	1.7	24
69	Facilitation of aggressive and sexual behaviors by saccharin deprivation in rats. Physiology and Behavior, 2004, 80, 531-539.	1.0	11
70	Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology, 2004, 47, 175-183.	2.0	35
71	Naltrexone for heroin dependence treatment in St. Petersburg, Russia. Journal of Substance Abuse Treatment, 2004, 26, 285-294.	1.5	96
72	The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats. Behavioural Pharmacology, 2004, 15, 273-278.	0.8	10

#	Article	IF	Citations
73	Effects of NMDA receptor channel blockers, MK-801 and memantine, on locomotor activity and tolerance to delay of reward in Wistarâ˜Kyoto and spontaneously hypertensive rats. Behavioural Pharmacology, 2004, 15, 263-271.	0.8	22
74	Effects of morphine on formalin-induced nociception in rats. European Journal of Pharmacology, 2003, 462, 109-113.	1.7	27
75	Decreased prepulse inhibition during nicotine withdrawal in DBA/2J mice is reversed by nicotine self-administration. European Journal of Pharmacology, 2003, 472, 99-110.	1.7	31
76	Facilitation of electrical brain self-stimulation behavior by abused solvents. Pharmacology Biochemistry and Behavior, 2003, 75, 199-208.	1.3	24
77	Lack of depression-like effects of saccharin deprivation in rats: Forced swim test, differential reinforcement of low rates and intracranial self-stimulation procedures.. Behavioral Neuroscience, 2003, 117, 970-977.	0.6	6
78	A Pilot Study of Memantine Effects on Protracted Withdrawal (Syndrome of Anhedonia) in Heroin Addicts. Addictive Disorders and Their Treatment, 2002, 1, 143-146.	0.5	20
79	Site-Selective N-Methyl-?-Aspartate and Î±-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionate Antagonists Produce Distinct Effects in Rats Performing Complex Discriminations. Neurobiology of Learning and Memory, 2002, 78, 347-364.	1.0	9
80	Opioid-NMDA receptor interactions may clarify conditioned (associative) components of opioid analgesic tolerance. Neuroscience and Biobehavioral Reviews, 2001, 25, 343-353.	2.9	36
81	Competitive and noncompetitive NMDA antagonist effects in rats trained to discriminate lever-press counts. Pharmacology Biochemistry and Behavior, 2001, 69, 493-502.	1.3	24
82	Motor impairment produced by ethanol and site-selective NMDA receptor antagonists in mice. Alcohol, 2000, 20, 31-36.	0.8	7
83	Decrement in Operant Performance Produced by NMDA Receptor Antagonists in the Rat. Pharmacology Biochemistry and Behavior, 2000, 65, 611-620.	1.3	1
84	Effects of NMDA receptor antagonists on cocaine-conditioned motor activity in rats. European Journal of Pharmacology, 2000, 390, 303-311.	1.7	31
85	Antinociceptive activity of combination of morphine and NMDA receptor antagonists depends on the inter-injection interval. European Journal of Pharmacology, 2000, 396, 77-83.	1.7	26
86	Pretreatment with morphine potentiates naloxone-conditioned place aversion in mice: effects of NMDA receptor antagonists. European Journal of Pharmacology, 2000, 406, 227-232.	1.7	23
87	Short-acting NMDA receptor antagonist MRZ 2/576 produces prolonged suppression of morphine withdrawal in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 361, 279-282.	1.4	16
88	Effects of short-acting NMDA receptor antagonist MRZ 2/576 on morphine tolerance development in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 361, 573-577.	1.4	8
89	Effects of test conditions on the outcome of place conditioning with morphine and naltrexone in mice. Psychopharmacology, 1999, 141, 118-122.	1.5	28
90	Low-affinity NMDA receptor channel blockers inhibit acquisition of intravenous morphine self-administration in naive mice. European Journal of Pharmacology, 1999, 378, 1-8.	1.7	45

#	Article	IF	Citations
91	Differential effects of nitric oxide synthase inhibitor, 7-nitroindazole, on discriminative stimulus and somatic effects of naloxone in morphine-dependent rats. European Journal of Pharmacology, 1999, 377, 183-186.	1.7	8
92	Effects of Calcium Channel Blockers on Behaviors Induced by the N-Methyl-d-Aspartate Receptor Antagonist, Dizocilpine, in Rats. Pharmacology Biochemistry and Behavior, 1999, 63, 569-580.	1.3	11
93	Morphine Tolerance and Dependence in Mice with History of Repeated Exposures to NMDA Receptor Channel Blockers. Pharmacology Biochemistry and Behavior, 1999, 63, 613-619.	1.3	10
94	Effects of abused drugs on thresholds and breaking points of intracranial self-stimulation in rats. European Neuropsychopharmacology, 1999, 9, 377-383.	0.3	44
95	Prolongation of morphine analgesia by competitive NMDA receptor antagonist d-CPPene (SDZ EAA 494) in rats. European Journal of Pharmacology, 1998, 351, 299-305.	1.7	29
96	Place conditioning of mice with the NMDA receptor antagonists, eliprodil and dizocilpine. European Journal of Pharmacology, 1998, 362, 103-110.	1.7	9
97	Interactions Between N-Methyl-?-Aspartate Receptor Antagonists and the Discriminative Stimulus Effects of Morphine in Rats. Pharmacology Biochemistry and Behavior, 1998, 60, 507-517.	1.3	11
98	NMDA receptor antagonists prevent conditioned activation of intracranial self-stimulation in rats. European Journal of Pharmacology, 1997, 326, 109-112.	1.7	9
99	The expression of both amphetamine-conditioned place preference and pentylenetetrazol-conditioned place aversion is attenuated by the NMDA receptor antagonist (Â±)-CPP. Drug and Alcohol Dependence, 1996, 41, 85-88.	1.6	20
100	Intraaccumbens administration of NMDA receptor antagonist (Â±)-CPP prevents locomotor activation conditioned by morphine and amphetamine in rats. Pharmacology Biochemistry and Behavior, 1996, 55, 203-207.	1.3	28
101	Classical conditioning of electrical self-stimulation of ventral tegmental area to brief visual stimuli in rats. Journal of Neuroscience Methods, 1996, 70, 1-4.	1.3	1
102	Behavioral effects of MK-801 in morphine-dependent and non-dependent mice. Life Sciences, 1995, 58, PL55-PL61.	2.0	2
103	Subchronic morphine increases amphetamine-induced potentiation of brain stimulation reward: reversal by DNQX. European Neuropsychopharmacology, 1995, 5, 89-93.	0.3	3
104	Tolerance for opiate analgesia: Complex effect of antagonists of receptors for excitatory amino acids. Bulletin of Experimental Biology and Medicine, 1994, 117, 491-493.	0.3	0
105	Excitatory amino acid receptor antagonist kynurenic acid attenuates rewarding potential of morphine. European Journal of Pharmacology, 1994, 264, 233-239.	1.7	56
106	In search of the mechanisms of ketamineâ€™s antidepressant effects: How robust is the evidence behind the mTor activation hypothesis. F1000Research, 0, 5, 634.	0.8	28